We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
Zoetis Inc. (ZTS - Free Report) is scheduled to report third-quarter 2020 results on Nov 5, before market open.
The company flaunts an excellent earnings surprise history, surpassing expectations in the trailing four quarters by 13.24%, on average. In the last reported quarter, the company delivered an earnings surprise of 34.85%.
Shares of Zoetis have increased 19.8% in the year so far against the industry’s decline of 11.4%.
Let's see how things are shaping up for this announcement.
What Our Model Indicates
Our proven model predicts an earnings beat for Zoetis this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here as you will see below.
Earnings ESP: Zoetis has an Earnings ESP of +3.98%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Factors to Consider
Zoetis derives a majority of revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports results under two geographical operating segments, namely the United States and International. Solid sales from the dermatology portfolio strengthened the United States segment in the last reported quarter, a trend that most likely continued in the third quarter too. The company’s companion animal business has been performing well too. Simparica franchise, including some initial stocking of Simparica Trio, the new triple combination parasiticide, continues to drive growth for the companion animal portfolio.
However, sales of livestock products declined in the last reported quarter due to disruptions in the food supply chain including reduced producer processing due to capacity and continued channel migration from dining out to preparing food at home impacted producer profitability. This resulted in a decline across each of the cattle, swine and poultry portfolios. The trend might have persisted in the third quarter and negatively impacted sales.
For the International segment, sales of companion animal products declined in the second quarter due to the impact of COVID-19 and social distancing measures. The trend is expected to have continued in the third quarter. Sales of livestock should also witness a declining trend. However, the dermatology portfolio is expected to have gained in the third quarter.
During the second quarter, the company stated that it expects overall revenue growth for the remainder of 2020 to be driven largely by companion animal products, especially parasiticides, and its key dermatology portfolio. Hence, the company raised its guidance to reflect its current outlook for the year. The company expects adjusted earnings of $3.52-$3.68 per share for 2020 compared with the previous guidance of $3.17-$3.42.
The company raised its revenue guidance for 2020 to $6.300-$6.475 billion from the previous range of $5.950-$6.250 billion.
Other Stocks to Consider
Here are some other biotech stocks that have the right mix of elements to beat on earnings this time around:
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
Zoetis Inc. (ZTS - Free Report) is scheduled to report third-quarter 2020 results on Nov 5, before market open.
The company flaunts an excellent earnings surprise history, surpassing expectations in the trailing four quarters by 13.24%, on average. In the last reported quarter, the company delivered an earnings surprise of 34.85%.
Shares of Zoetis have increased 19.8% in the year so far against the industry’s decline of 11.4%.
Let's see how things are shaping up for this announcement.
What Our Model Indicates
Our proven model predicts an earnings beat for Zoetis this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here as you will see below.
Earnings ESP: Zoetis has an Earnings ESP of +3.98%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Factors to Consider
Zoetis derives a majority of revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports results under two geographical operating segments, namely the United States and International. Solid sales from the dermatology portfolio strengthened the United States segment in the last reported quarter, a trend that most likely continued in the third quarter too. The company’s companion animal business has been performing well too. Simparica franchise, including some initial stocking of Simparica Trio, the new triple combination parasiticide, continues to drive growth for the companion animal portfolio.
However, sales of livestock products declined in the last reported quarter due to disruptions in the food supply chain including reduced producer processing due to capacity and continued channel migration from dining out to preparing food at home impacted producer profitability. This resulted in a decline across each of the cattle, swine and poultry portfolios. The trend might have persisted in the third quarter and negatively impacted sales.
For the International segment, sales of companion animal products declined in the second quarter due to the impact of COVID-19 and social distancing measures. The trend is expected to have continued in the third quarter. Sales of livestock should also witness a declining trend. However, the dermatology portfolio is expected to have gained in the third quarter.
During the second quarter, the company stated that it expects overall revenue growth for the remainder of 2020 to be driven largely by companion animal products, especially parasiticides, and its key dermatology portfolio. Hence, the company raised its guidance to reflect its current outlook for the year. The company expects adjusted earnings of $3.52-$3.68 per share for 2020 compared with the previous guidance of $3.17-$3.42.
The company raised its revenue guidance for 2020 to $6.300-$6.475 billion from the previous range of $5.950-$6.250 billion.
Other Stocks to Consider
Here are some other biotech stocks that have the right mix of elements to beat on earnings this time around:
Bristol-Myers’ Squibb (BMY - Free Report) has an Earnings ESP of +0.44% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Axcella Health Inc. has an Earnings ESP of +10.90% and a Zacks Rank of 3.
Aeglea Bio Therapeutics has an Earnings ESP of +13.16% and is Zacks #3 Ranked.
Zoetis Inc. Price and Consensus
Zoetis Inc. price-consensus-chart | Zoetis Inc. Quote
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>